Esperion Therapeutics, Inc.

NasdaqGM:ESPR Stock Report

Market Cap: US$489.1m

Esperion Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGM:ESPR Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
17 Mar 26SellUS$17,377Benjamin HalladayIndividual6,424US$2.71
17 Mar 26SellUS$69,547Sheldon KoenigIndividual25,578US$2.72
17 Mar 26SellUS$15,429Benjamin LookerIndividual5,708US$2.70
20 Jan 26SellUS$4,868Benjamin LookerIndividual1,689US$2.88
17 Dec 25SellUS$23,898Benjamin LookerIndividual6,517US$3.67
17 Dec 25SellUS$26,905Benjamin HalladayIndividual7,337US$3.67
17 Dec 25SellUS$177,200Sheldon KoenigIndividual48,244US$3.67
17 Oct 25SellUS$3,275Benjamin LookerIndividual1,248US$2.62
17 Sep 25SellUS$17,573Benjamin LookerIndividual6,267US$2.80
17 Sep 25SellUS$79,254Sheldon KoenigIndividual28,427US$2.79
17 Sep 25SellUS$19,785Benjamin HalladayIndividual7,046US$2.81
17 Jul 25SellUS$1,470Benjamin LookerIndividual1,304US$1.13
17 Jul 25SellUS$12Benjamin HalladayIndividual11US$1.12
17 Jun 25SellUS$8,328Benjamin HalladayIndividual7,229US$1.15
17 Jun 25SellUS$33,796Sheldon KoenigIndividual30,474US$1.11
17 Jun 25SellUS$7,398Benjamin LookerIndividual6,422US$1.15

Insider Trading Volume

Insider Buying: ESPR insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of ESPR?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders2,249,5000.874%
General Public96,000,83037.3%
Institutions159,154,54661.8%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 29.9%.

Top Shareholders

Top 25 shareholders own 53.67% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
6.87%
BlackRock, Inc.
17,682,201US$33.6m19.2%no data
6.13%
Wasatch Advisors LP
15,768,897US$30.0m66.9%0.1%
5.81%
The Vanguard Group, Inc.
14,945,454US$28.4m23.6%no data
4.62%
Two Seas Capital LP
11,902,521US$22.6m22.1%1.1%
2.68%
D. E. Shaw & Co., L.P.
6,903,483US$13.1m3,210%0.01%
2.32%
OrbiMed Advisors LLC
5,965,498US$11.3m0%0.16%
2.3%
State Street Global Advisors, Inc.
5,930,296US$11.3m32.4%no data
2.23%
Geode Capital Management, LLC
5,737,651US$10.9m20.8%no data
2.13%
Marshall Wace LLP
5,471,611US$10.4m117%0.01%
1.84%
Two Sigma Investments, LP
4,742,082US$9.0m112%0.01%
1.71%
PenderFund Capital Management Ltd.
4,391,926US$8.3m-34.2%1.52%
1.55%
Aigh Capital Management, LLC
4,000,000US$7.6m33.3%1.42%
1.53%
Millennium Management LLC
3,932,274US$7.5m303%no data
1.5%
Eversept Partners, L.P.
3,851,133US$7.3m0%0.45%
1.4%
Royce & Associates, LP
3,601,523US$6.8m57%0.05%
1.37%
Teachers Insurance and Annuity Association-College Retirement Equities Fund
3,536,121US$6.7m-2.7%no data
1.36%
Two Sigma Advisers, LP
3,505,200US$6.7m83.7%0.01%
1.35%
Morgan Stanley
3,472,251US$6.6m-14%no data
1%
The Goldman Sachs Group, Inc.
2,578,278US$4.9m0%no data
0.85%
Renaissance Technologies LLC
2,194,600US$4.2m184%0.01%
0.81%
Edward Jones Trust Company
2,094,412US$4.0m168,000%no data
0.78%
Northern Trust Global Investments
1,995,706US$3.8m7.97%no data
0.61%
Walleye Capital LLC
1,573,079US$3.0m393%0.01%
0.47%
Velan Capital Partners LP
1,210,000US$2.3m0%1.42%
0.45%
Voleon Capital Management LP
1,154,390US$2.2m455%0.05%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/04/28 09:21
End of Day Share Price 2026/04/27 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Esperion Therapeutics, Inc. is covered by 16 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason ZemanskyBofA Global Research
Kristen KluskaCantor Fitzgerald & Co.
Jason ButlerCitizens JMP Securities, LLC